Imunon (IMNN) Other Non-Current Assets (2011 - 2026)
Imunon's (IMNN) quarterly Other Non-Current Assets came in at $937892.0 in Q1 2026, up 1775.78% YoY from $50000.0 in Q1 2025, and down 9.33% on a QoQ basis from $1.0 million in Q4 2025.
Imunon (IMNN) Other Non-Current Assets (2011 - 2026) Analysis & Trends
Imunon (IMNN) has 16 years of Other Non-Current Assets data on file, last reported at $937892.0 in Q1 2026.
- Quarterly Other Non-Current Assets rose 1775.78% year-over-year to $937892.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $937892.0 (up 1775.78% YoY) and the FY2025 annual result came in at $1.0 million, down 11.37% from the prior year.
- Other Non-Current Assets retreated to $937892.0 in Q1 2026, from $1.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $19.9 million in Q2 2022 to a low of $50000.0 in Q1 2023.
- A 5-year average of $3.3 million and a median of $689666.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets surged 33690.11% — and 2023, when it slumped 99.75%.
- Tracing IMNN's Other Non-Current Assets over 5 years: stood at $6.6 million in 2022, then plunged by 99.25% to $50000.0 in 2023, then soared by 2234.27% to $1.2 million in 2024, then retreated by 11.37% to $1.0 million in 2025, then declined by 9.33% to $937892.0 in 2026.
- The last three Other Non-Current Assets figures came in at $937892.0 (Q1 2026), $1.0 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Imunon | 8.42 Mn | 8.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 937,892.00 |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 1.13 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 50,000.00 |
| Dec 31, 2024 | 1.17 Mn |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 50,000.00 |
| Dec 31, 2023 | 50,000.00 |
| Sep 30, 2023 | 441,440.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 50,000.00 |
| Dec 31, 2022 | 6.65 Mn |
| Sep 30, 2022 | 19.75 Mn |
| Jun 30, 2022 | 19.86 Mn |
| Mar 31, 2022 | 58,761.00 |
| Dec 31, 2021 | 21.62 Mn |
| Sep 30, 2021 | 58,761.00 |
| Jun 30, 2021 | 58,761.00 |
| Mar 31, 2021 | 58,761.00 |